Australian oncology company Noxopharm (ASX:NOX) said on Friday that St. Vincent's Hospital Sydney has presented positive interim results from the LuPIN Phase 1/2 clinical trial at the ASCO Genitourinary Cancers (GU) Symposium 2020 held in San Francisco.

St. Vincent's Hospital Sydney is evaluating Noxopharm's lead drug candidate, Veyonda, in combination with 177Lu-PSMA-617, in 56 patients with late-stage metastatic castration-resistant prostate cancer (mCRPC) under the LuPIN study.

All patients had received and failed two prior lines of therapy (chemotherapy and androgen-signaling inhibitors), and most patients (29 of 32) had failed a third line of therapy (another chemotherapy) prior to entering the trial.

Noxopharm CEO Dr Graham Kelly commented that it is remarkable to deliver a meaningful anti-cancer response for at least 50% of patients in late-stage prostate cancer, where the disease involves a number of secondaries in the skeleton, which are a significant and poorly accessible tumour load. A median overall survival of 17.1 months is remarkable for this novel radiosensitizing and immuno-oncology drug.